Observational studyBMC pregnancy and childbirth2025
Improved maternal outcome in placenta accreta spectrum disorders: a single-institute observational cohort study.
Observational study in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Antepartum Anemia on Maternal and Perinatal Outcomes in Women with Placenta Accreta Spectrum: A Multicenter Study.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo describe the evolution and outcomes of protocol-orientated multidisciplinary quality improvement for clinically confirmed placenta accreta spectrum (PAS) disorders mainly receiving uterine preservation.
methodsThis single-institute, retrospective cohort study compared clinical outcomes of patients within three periods of 2013-2016 (initial period), 2017-2019 (transition period), and 2020-2023 (current period) during January 1st, 2013, to December 31st ,2023. The quality improvement elements were introduced mainly in the transition period, including optimization of peripartum care, prenatal diagnosis, surgical plan and preparation of autologous blood products. The primary outcomes included early composite maternal morbidity and uterine preservation rate. Meanwhile, secondary outcomes were late composite maternal morbidity, estimated blood loss and allogenic blood transfusion.
resultsThis study enrolled 474 consecutive patients, involving 153 patients in initial period, 202 patients in transition period and 119 patients in current period. There was a large proportion of patients (97.5%) receiving surgery for uterine preservation in current period than in initial period (81.0%) and transition period (93.6%) (P < 0.001). Early maternal morbidity gradually decreased from 23.5% in initial period to 17.8% and 11.8% in transition period and current period (P = 0.044). The major contributors included reduced transfusion of 4 or more red blood cells (22.9% vs. 16.3% vs. 10.9%; P = 0.032) and early reoperation (5.2% vs. 1.5% vs. 0.8%; P = 0.034). There was also increase of 400 ml in intraoperative blood loss and overall blood loss (P = 0.003 and P = 0.034, respectively), which might relate with less application of invasive hemostatic procedures, including preoperative balloon occlusion and intrauterine tamponade. However, no significant difference in allogenic blood transfusion was revealed due to raising in preoperative hemoglobin level (107 g/L vs. 110 g/L vs. 113 g/L; P = 0.001) and establishing various forms of autologous blood preparation.
conclusionThe implementation of quality improvement elements may result in lower composite maternal morbidity with more uterine preservation, coupled with less application of MRI and invasive intraoperative hemostatic procedures. Our findings suggest that institutional quality improvement may reduce morbidity and improve uterine preservation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.